Please assess the completion status of the following clinical trial:

Trial Title: AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed low-grade neuroendocrine neoplasm~* Measurable disease~* Radiographic evidence of disease progression after any prior systemic therapy, chemoembolization, bland embolization, or observation, defined by either of the following:~  * Appearance of a new lesion~ * At least 20% increase in the longest diameter of any previously documented lesion or in the sum of the longest diameters of multiple lesions~* Tissue block from original diagnostic or surgical specimen required~* Concurrent stable-dose octreotide acetate required~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Negative pregnancy test~* Fertile patients must use effective contraception~* Must be able to receive a contrast-enhanced CT scan~* Absolute neutrophil count ≥ 1,000/mm³~* Platelet count ≥ 75,000/mm³~* Hemoglobin level ≥ 8.0 g/dL~* Bilirubin ≤ 2.0 times upper limit of normal (ULN)~* Aspartate aminotransferase (AST) ≤ 3 times ULN (5 times ULN if liver metastases are present)~* Left Ventricular Ejection Fraction (LVEF) ≥ institutional lower limit of normal as evaluated by echocardiography or multigated acquisition (MUGA) scan~* No history of uncontrolled hypertension (resting blood pressure \> 150/90 mm Hg)~  * Antihypertensive medications allowed if patients is stable on their current dose~* One prior systemic chemotherapy regimen for low-grade neuroendocrine neoplasm allowed~  * Chemoembolization is not considered systemic chemotherapy~* At least 4 weeks since prior major surgery, chemotherapy, radiation therapy, other systemic therapy, or local liver therapy~Exclusion criteria:~* Prior procedures that would adversely affect intestinal absorption~* Prior anti-vascular endothelial growth factors~* Concurrent chemotherapy or radiation therapy~* History of the following within the past 12 months:~  * New York Heart Association class III or IV congestive heart failure~ * Unstable angina pectoris~ * Myocardial infarction~ * Symptomatic cardiac arrhythmia~ * Cerebrovascular accident or transient ischemic attack~ * Arterial or venous thrombosis~* Known history of allergic reactions to AMG 706 or derivatives or to octreotide acetate injections~* Gastrointestinal tract disease resulting in an inability to take oral medication (i.e., ulcerative disease, uncontrolled nausea, vomiting, or diarrhea, bowel obstruction, or inability to swallow tablets)~* Pregnant or nursing~* Small cell lung cancer, medullary thyroid cancer, paraganglioma, or pheochromocytoma~* Requirement for intravenous alimentation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMG 706+Octreotide (Type: EXPERIMENTAL): Patients receive oral AMG 706 and octreotide acetate intramuscularly (IM) once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the morning. AMG 706 was taken daily without breaks in treatment.~One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).